Data as of Oct 30
| +0.19 / +2.81%|
The 9 analysts offering 12-month price forecasts for AcelRx Pharmaceuticals Inc have a median target of 12.00, with a high estimate of 15.00 and a low estimate of 6.00. The median estimate represents a +72.91% increase from the last price of 6.94.
The current consensus among 9 polled investment analysts is to Buy stock in AcelRx Pharmaceuticals Inc. This rating has held steady since October, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.